Condition
Malignant Hematological Diseases
Total Trials
3
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 3 (1)
Trial Status
Recruiting2
Unknown1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06548958Not ApplicableRecruitingPrimary
A Single-Arm, Prospective Study of TBI+BUMEL as Conditioning for SCT2 in Patients With Malignant Hematologic Diseases
NCT05929092Not ApplicableRecruiting
TFBC Combined With UCBT in the Treatment of High-risk Malignant Hematological Diseases
NCT01959100Phase 3UnknownPrimary
Efficacy of Azithromycin to Prevent Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation
Showing all 3 trials